Industry
Biotechnology
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Loading...
Open
2.30
Mkt cap
182M
Volume
2.8M
High
2.44
P/E Ratio
-1.28
52-wk high
16.24
Low
2.24
Div yield
N/A
52-wk low
2.24
Portfolio Pulse from Avi Kapoor
August 14, 2024 | 9:35 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 8:13 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 7:05 pm
Portfolio Pulse from Benzinga Newsdesk
July 24, 2024 | 10:07 am
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 2:54 pm
Portfolio Pulse from Benzinga Newsdesk
July 16, 2024 | 10:03 am
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 9:28 am
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 5:51 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 10:04 am
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 10:04 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.